We are proud to be one of the largest prospective studies of patients receiving these drugs in the world, with over 30,000 patients registered in the study since it started in 2001.

This epidemiological study is a unique collaboration between The University of Manchester, the British Society for Rheumatology and the pharmaceutical industry. All consultant rheumatologists in the UK who prescribe biologic, biosimilar or JAK inhibitors have an opportunity to participate in the register, supported by allied health professionals.

We capture data from rheumatology teams who are looking after patients with RA, as well as asking patients themselves to complete questionnaires on how they are feeling. We also receive clinical data from national NHS databases (including NHS England) to enhance the data we collect.